The approval of Aβ-clearing antibodies like Leqembi (lecanemab) and Kisunla (donanemab) marked a landmark shift toward disease-modifying therapies in Alzheimer’s,…
HOME > REGULATORY
REGULATORY
- PMDA Reviewing Anaphylaxis Risk for Xocova
June 29, 2023
- MHLW Shuffles Senior Bureaucrats, Jo Tapped as Chief of Pharma Bureau
June 28, 2023
- After Years of Debates, Wholesalers’ Negative Primary Margins Remain a Problem
June 28, 2023
- SCARDA, CEPI Ink Pact to Beef Up Collab for Vaccine Development
June 28, 2023
- Japan OKs Oncaspar, Lytgobi, Litfulo, Rinvoq/Keytruda Label Expansions and More
June 27, 2023
- Ryukaikon Calls for Correcting Excessive Yakkasa by Revising Distribution Guidelines
June 27, 2023
- Ryukaikon to Discuss Drug Categories to Be Separated from Bundled Trades
June 27, 2023
- Japan Reports World’s 1st Death from Oz Virus
June 26, 2023
- PMDA Reviewing Safety Risks for 10 Statin Drugs, Tirzepatide
June 26, 2023
- Will Pilot Switch Proposal Break Stalemate in Emergency Contraceptive Debate?
June 23, 2023
- Avigan, 3 Other Drugs Get Orphan Status in Japan
June 23, 2023
- Chuikyo Kicks Off Debates toward FY2024 Drug Price Reform
June 22, 2023
- Chuikyo OKs Drug Price Survey Plan for FY2024 Revision
June 22, 2023
- Japan Diet Ends Ordinary Session, All 7 MHLW-Submitted Bills Enacted
June 22, 2023
- MHLW Panel Discusses 6 Risks to Drug Supplies; Need for Industry Consolidation Raised
June 21, 2023
- MHLW to Set Up Separate Forums Focused on Generics and Drug Lags to Execute Expert Panel Proposals
June 21, 2023
- Ryukaikon to Meet June 26 to Discuss Expert Panel Proposals
June 21, 2023
- MHLW Study Group to Develop Company Indicators for Generic Supply Systems in FY2023
June 20, 2023
- MHLW Study Group Proposes Flexibility in Launch Premium Criteria, Broader Comparators
June 20, 2023
- MHLW Starts Clinical Study on Mpox Vaccine for People with High Infection Risks
June 19, 2023
ページ
PHARMA JAPAN welcomes JETRO New York’s Shunsuke Tani as a guest columnist. In occasional contributions, Tani will share his perspectives on US pharmaceutical policy, industry developments, and life in America, drawing on his firsthand experience in the US.---Hello from New…
Japan should fundamentally overhaul its cost-effectiveness assessment (CEA) scheme while putting a hold on CEA-based price adjustments, a new ruling…
Japanese Prime Minister Sanae Takaichi said on October 14 that the government will consider the necessary measures for the FY2027…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…